{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:41Z","timestamp":1786122101309,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nontuberculous mycobacteria (NTM) are environmental organisms that become opportunistic pathogens in certain populations. NTM prevalence has increased globally, likely due to increased diagnostic testing and the availability of population-based studies. Current literature on oncology patients is minimal and represents a unique study area. Here we present the epidemiology and treatment of NTM infection cases at a National Cancer Institute\u2013designated comprehensive cancer center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-center cohort study of adults with microbiologically proven NTM infections presenting from 2020 to 2023. Epidemiologic and treatment-related data were retrieved from the electronic medical record and evaluated to illustrate institutional patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 93 patients met assessment criteria, with most (74 of 93 [80%]) having a past or active cancer. Mycobacterium avium complex (47 of 93 [51%]) and Mycobacterium abscessus group (28 of 93 [30%]) were the most common isolates. The majority were pulmonary infections (75 of 93 [81%]), with the integument accounting for most extrapulmonary sites (14 of 18 [78%]). Of 93 patients, 49 (53%]) received therapy, with many (41 of 49 [84%]) receiving \u22653 agents. Thirty-nine (80%]) required an initial regimen modification, and 13 (27%) received dual \u03b2-lactam therapy (frequently including meropenem). Of treated patients, 36 (73%) demonstrated improved symptoms, 18 (37%) improved or partially improved radiologic change, and 19 (39%]) sustained culture conversion to negative at the evaluation time point; 13 (27%) died or were lost to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our report offers one of the largest single-center epidemiologic perspectives on NTM infections in oncology patients. It offers unique insight into treatment practices in this population, particularly regarding dual \u03b2-lactam therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag467","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T11:30:21Z","timestamp":1785065421000},"source":"Crossref","is-referenced-by-count":0,"title":["Nontuberculous Mycobacterial Infections at a National Cancer Institute\u2013Designated Comprehensive Cancer Center in Florida"],"prefix":"10.1093","volume":"13","author":[{"given":"Yanina","family":"Pasikhova","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Moffitt Cancer Center , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4763-7223","authenticated-orcid":false,"given":"Matthew","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Moffitt Cancer Center , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-9605","authenticated-orcid":false,"given":"Austin","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Moffitt Cancer Center , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-5848","authenticated-orcid":false,"given":"Guy","family":"Handley","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4837-5680","authenticated-orcid":false,"given":"Misbahuddin","family":"Syed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Moffitt Cancer Center , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-0689","authenticated-orcid":false,"given":"Anthony P","family":"Cannella","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Internal Medicine, University of South Florida Morsani College of Medicine , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026080703471314000_ofag467-B1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"2026080703471314000_ofag467-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0033-1333567","article-title":"Update on the epidemiology of pulmonary nontuberculous mycobacterial infections","volume":"34","author":"Kendall","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"2026080703471314000_ofag467-B3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080703471314000_ofag467-B4","first-page":"977","article-title":"Pulmonary disease by non-tuberculous mycobacteria\u2014clinical management, unmet needs and future perspectives","volume":"11","author":"Larsson","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2026080703471314000_ofag467-B5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"key":"2026080703471314000_ofag467-B6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12879-018-3043-7","article-title":"Increasing nontuberculous mycobacteria reporting rates and species diversity identified in clinical laboratory reports","volume":"18","author":"Donohue","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026080703471314000_ofag467-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3201\/eid170310060","article-title":"Nontuberculous mycobacteria in respiratory tract infections, Eastern Asia","volume":"17","author":"Simons","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2026080703471314000_ofag467-B8","article-title":"The epidemiology, demographics, and comorbidities of pulmonary and extra-pulmonary non-tuberculous mycobacterial infections at a large central Florida academic hospital","volume":"25","author":"Garcia","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026080703471314000_ofag467-B9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026080703471314000_ofag467-B10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026080703471314000_ofag467-B11","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026080703471314000_ofag467-B12","article-title":"Extrapulmonary nontuberculous mycobacterial infections: a guide for the general physician","volume":"24","author":"Malhotra","year":"2024","journal-title":"Clin Med (Lond)"},{"key":"2026080703471314000_ofag467-B13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1513\/AnnalsATS.202003-222CME","article-title":"Summary for clinicians: 2020 clinical practice guideline summary for the treatment of nontuberculous mycobacterial pulmonary disease","volume":"17","author":"Kurz","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026080703471314000_ofag467-B14","article-title":"Treatment of non-tuberculosis mycobacteria skin infections","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026080703471314000_ofag467-B15","first-page":"2988","article-title":"A Japanese retrospective study of non-tuberculous mycobacterial infection in children, adolescents, and young adult patients with hematologic-oncologic diseases","volume":"109","author":"Tsumura","year":"2024","journal-title":"Haematologica"},{"key":"2026080703471314000_ofag467-B16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the L,D-transpeptidases and D,D-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080703471314000_ofag467-B17","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae142","article-title":"The use of dual \u03b2-lactams to restore susceptibility of Mycobacterium avium complex","volume":"6","author":"Al-Jabri","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026080703471314000_ofag467-B18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/ciab535","article-title":"\"One-two punch\u201d: synergistic \u03b2-lactam combinations for Mycobacterium abscessus and target redundancy in the inhibition of peptidoglycan synthesis enzymes","volume":"73","author":"Nguyen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026080703471314000_ofag467-B19","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00319-24","article-title":"Dual \u03b2-lactam for treatment of pulmonary Mycobacterium abscessus in a child","volume":"68","author":"Becken","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080703471314000_ofag467-B20","article-title":"A 40-year-old female with Mycobacterium abscessus successfully treated with a dual beta-lactam combination","volume":"15","author":"Moguillansky","year":"2023","journal-title":"Cureus"},{"key":"2026080703471314000_ofag467-B21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad312","article-title":"Eradicating pulmonary Mycobacterium abscessus: the promise of dual \u03b2-lactam therapy","volume":"10","author":"Alahmdi","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026080703471314000_ofag467-B22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cmi.2024.03.019","article-title":"Dual \u03b2-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease","volume":"30","author":"Pozuelo Torres","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026080703471314000_ofag467-B23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/JCM.00298-16","article-title":"In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and Nocardia by use of broth microdilution and Etest","volume":"54","author":"Brown-Elliott","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2026080703471314000_ofag467-B24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00174-24","article-title":"In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus","volume":"68","author":"Chen","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080703471314000_ofag467-B25","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4471","article-title":"Stability and degradation products of imipenem applying high-resolution mass spectrometry: an analytical study focused on solutions for infusion","volume":"33","author":"de Souza Barbosa","year":"2019","journal-title":"Biomed Chromatogr"},{"key":"2026080703471314000_ofag467-B26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.29090\/psa.2024.02.24.1651","article-title":"Comparative stability of imipenem and meropenem solutions for extended infusion administration","volume":"51","author":"Katip","year":"2024","journal-title":"Pharm Sci Asia"},{"key":"2026080703471314000_ofag467-B27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.medmal.2020.01.001","article-title":"Comparative review of imipenem\/cilastatin versus meropenem","volume":"50","author":"Salmon-Rousseau","year":"2020","journal-title":"Med Mal Infect"},{"key":"2026080703471314000_ofag467-B28","article-title":"A review of evidence, antimicrobial stability, and feasibility considerations for OPAT continuous infusion","volume":"10","author":"Van Abel","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"2026080703471314000_ofag467-B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106299","article-title":"Outpatient parenteral antimicrobial therapy with carbapenems: a systematic review","volume":"89","author":"Wolie","year":"2024","journal-title":"J Infect"},{"key":"2026080703471314000_ofag467-B30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae128","article-title":"Pharmacotherapeutic considerations in the treatment of nontuberculous mycobacterial infections: a primer for clinicians","volume":"11","author":"Cimino","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026080703471314000_ofag467-B31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.977","article-title":"P-783. Bedaquiline for the treatment of non-tuberculous mycobacterial infections: retrospective analysis from a large healthcare system","volume":"12","author":"Hysell","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026080703471314000_ofag467-B32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkad372","article-title":"Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis","volume":"79","author":"Omar","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026080703471314000_ofag467-B33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40121-022-00750-5","article-title":"Contemporary pharmacotherapies for nontuberculosis mycobacterial infections: a narrative review","volume":"12","author":"Johnson","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026080703471314000_ofag467-B34","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.990","article-title":"P-798. Non-tuberculosis mycobacterial infections at a National Cancer Institute-designated comprehensive cancer center in Florida","volume":"12","author":"Pasikhova","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag467\/70335579\/ofag467.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag467\/70335579\/ofag467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag467\/70335579\/ofag467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:47:24Z","timestamp":1786088844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag467\/8746683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag467","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,29]]},"article-number":"ofag467"}}